Key facts
- Notable investors include Ben Franklin Technology Partners of Northeastern Pennsylvania.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for MTF Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for MTF Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MTF Biologics
Operator of a biotechnology firm intended for tissue and organ transplantation and related research. The company specializes in graft matching, offering orthopedic surgeons anatomically-matched allograft tissues, including meniscal and osteochondral grafts, which help eliminate the need for extensive modifications during surgery, enabling healthcare professionals to perform more efficient and effective transplants while enhancing patient outcomes.
- Sector
- Healthcare
- HQ
- Edison, NJ, United States
- Founded
- 1987
- Employees
- 1,235
- Website
- mtfbiologics.org/
- Ownership
- Privately Held (backing)
MTF Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MTF Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MTF Biologics in its N-PORT filings yet. We sweep new filings monthly.